866-997-4948(US-Canada Toll Free)

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2018

Published By :

Global Markets Direct

Published Date : Mar 2018

Category :

Pharmaceutical

No. of Pages : 55 Pages

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2018, provides an overview of the Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline landscape.

Systemic onset juvenile idiopathic arthritis (also known as Systemic juvenile idiopathic arthritis (sJIA)) is a disorder featuring inflammation, characterized by high spiking fevers, salmon-colored rash that comes and goes, and arthritis. Symptoms are extreme fatigue accompanied by high fevers that rise daily to 102 F (39 C) or even higher and rapidly return to normal levels or below. Fever spikes often occur at approximately the same time every day. A faint salmon colored skin rash characteristically comes and goes and does not itch. Poor appetite, nausea, and weight loss are common. There is also commonly swelling of the lymph glands, enlargement of the spleen and liver, and sore throat. Some patients develop inflammation around the heart (pericarditis) and lungs (pleuritis), with occasional fluid accumulation around heart (pericardial effusion) and lungs (pleural effusion).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 1, 5 and 1 respectively.

Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Systemic Idiopathic Juvenile Arthritis - Overview
Systemic Idiopathic Juvenile Arthritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Systemic Idiopathic Juvenile Arthritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Systemic Idiopathic Juvenile Arthritis - Companies Involved in Therapeutics Development
Alteogen Inc
Johnson & Johnson
Livzon Pharmaceutical Group Inc
Mycenax Biotech Inc
Novartis AG
Oncobiologics Inc
Systemic Idiopathic Juvenile Arthritis - Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canakinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
golimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Systemic Idiopathic Juvenile Arthritis - Dormant Projects
Systemic Idiopathic Juvenile Arthritis - Discontinued Products
Systemic Idiopathic Juvenile Arthritis - Product Development Milestones
Featured News & Press Releases
Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris
May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis
Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials
Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012
Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Systemic Idiopathic Juvenile Arthritis - Pipeline by Alteogen Inc, H1 2018
Systemic Idiopathic Juvenile Arthritis - Pipeline by Johnson & Johnson, H1 2018
Systemic Idiopathic Juvenile Arthritis - Pipeline by Livzon Pharmaceutical Group Inc, H1 2018
Systemic Idiopathic Juvenile Arthritis - Pipeline by Mycenax Biotech Inc, H1 2018
Systemic Idiopathic Juvenile Arthritis - Pipeline by Novartis AG, H1 2018
Systemic Idiopathic Juvenile Arthritis - Pipeline by Oncobiologics Inc, H1 2018
Systemic Idiopathic Juvenile Arthritis - Dormant Projects, H1 2018
Systemic Idiopathic Juvenile Arthritis - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *